An observational, prospective cohort study to evaluate the long term safety and effectiveness of intravenous CT-P13 (biosimilar of infliximab) in patients with Crohn's Disease or Ulcerative Colitis

被引：1
|
作者：
Cheon, J. H. [1 ,2 ]
Kang, H. W. [3 ]
Lee, S. J. [4 ]
Kim, S. H. [5 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Inst Gastroenterol, Seoul, South Korea
[3] SMG SNU Boramae Med Ctr, Div Gastroenterol & Hepatol, Dept Internal Med, Seoul, South Korea
[4] CELLTRION Inc, Div Clin Dev, Incheon, South Korea
[5] CELLTRION Inc, Clin Planning, Incheon, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.482
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P358
引用
收藏
页码：S378 / S378
页数：1
相关论文
共 50 条
  • [41] Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness
    Jae Hee Cheon
    Seongsu Nah
    Hyoun Woo Kang
    Yun Jeong Lim
    Sang-Hoon Lee
    Sang Joon Lee
    Sung Hyun Kim
    Na Hyun Jung
    Jeong Eun Park
    Yeo Jin Lee
    Da Bee Jeon
    Yeon Mi Lee
    Jong Min Kim
    Sung-Hwan Park
    Advances in Therapy, 2021, 38 : 4366 - 4387
  • [42] Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease
    Lovero, Rosa
    Losurdo, Giuseppe
    La Fortezza, Rosa Federica
    Terracciano, Fulvia
    Biscaglia, Giuseppe
    Martino, Giuseppina
    Nardella, Marianna
    Di Leo, Alfredo
    Principi, Mariabeatrice
    Andriulli, Angelo
    Bossa, Fabrizio
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (02) : 201 - 207
  • [43] Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness
    Cheon, Jae Hee
    Nah, Seongsu
    Kang, Hyoun Woo
    Lim, Yun Jeong
    Lee, Sang-Hoon
    Lee, Sang Joon
    Kim, Sung Hyun
    Jung, Na Hyun
    Park, Jeong Eun
    Lee, Yeo Jin
    Jeon, Da Bee
    Lee, Yeon Mi
    Kim, Jong Min
    Park, Sung-Hwan
    ADVANCES IN THERAPY, 2021, 38 (08) : 4366 - 4387
  • [44] Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13
    Park, Won
    Miranda, Pedro
    Brzosko, Marek
    Wiland, Piotr
    Gutierrez-Urena, Sergio
    Mikazane, Helena
    Lee, Yeon-Ah
    Smiyan, Svitlana
    Lim, Mie-Jin
    Kadinov, Vladimir
    Abud-Mendoza, Carlos
    Son, YoungKi
    Yoo, Dae-Hyun
    Braun, Juergen
    ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3326 - 3326
  • [45] ECCO 2018: British Observational Study shows Comparability of Iinfliximab Biosimilar CT-P13 with Reference Infliximab and Adalimumab in Patient with Crohn's Disease (CD)
    不详
    VISCERAL MEDICINE, 2018, 34 (02) : 158 - 158
  • [46] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [47] Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar(CT-P13) in patients with inflammatory bowel disease
    María Fernanda Guerra Veloz
    Federico Argüelles-Arias
    Luisa Castro Laria
    Belén Maldonado Pérez
    Antonio Benítez Roldan
    Raúl Perea Amarillo
    Vicente Merino Bohórquez
    Miguel Angel Calleja
    ángel Caunedo álvarez
    ángel Vilches Arenas
    World Journal of Gastroenterology, 2018, (46) : 5288 - 5296
  • [48] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [49] Clinical Outcomes Following a Switch from RemicadeA® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study
    Smits, Lisa J. T.
    Derikx, Lauranne A. A. P.
    de Jong, Dirk J.
    Boshuizen, Ronald S.
    van Esch, Aura A. J.
    Drenth, Joost P. H.
    Hoentjen, Frank
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (11): : 1287 - 1293
  • [50] Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
    Guerra Veloz, Maria Fernanda
    Arguelles-Arias, Federico
    Castro Laria, Luisa
    Maldonado Perez, Belen
    Benitez Roldan, Antonio
    Perea Amarillo, Raul
    Merino Bohorquez, Vicente
    Angel Calleja, Miguel
    Caunedo Alvarez, Angel
    Vilches Arenas, Angel
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (46) : 5288 - 5296
12345